AbbVie’s $10.9B deal adds atopic dermatitis and asthma drugs to its immunology arsenal
AbbVie agreed to buy Apogee Therapeutics for $10.9 billion cash, adding a pipeline that includes a half‑life‑extended IL‑13 antibody for atopic dermatitis and an anti‑TSLP combo for asthma. The deal expands AbbVie’s immunology footprint and targets multi‑billion‑dollar markets, boosting long‑term shareholder value.